Pacific Biosciences of California, Inc. Stock News

New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale

More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine

Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio's Revio system, powering one of the largest studies of healthy aging to date Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio's Revio system, powering one of the largest studies of healthy aging to date

Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing

Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants Christian Henry - President, CEO & Director Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku, and I'm on the life science tools and diagnostics tea...

New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christian O. Henry - President, CEO & Director James R.